Novartis statement regarding competition authority

• Company assured to make clear legitimacy of its place and totally cooperating with authorities

Basel, September 15, 2022 — Novartis immediately confirms that it has been contacted by the Swiss Competition Commission (COMCO) which has initiated an investigation, in collaboration with the European Commission, into the assertion of a patent within the broader discipline of dermatology therapies. In reference to this investigation, COMCO representatives visited the corporate headquarters in Basel.

The opening of an investigation doesn’t suggest any discovering of wrongdoing or any monetary influence. Novartis is totally cooperating with the authorities and is assured to make clear the legitimacy of its place. As that is an ongoing investigation in its early levels, we is not going to remark additional at this cut-off date.

Disclaimer

This media replace accommodates forward-looking statements throughout the which means of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can typically be recognized by phrases equivalent to “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or related phrases, or by categorical or implied discussions regarding potential advertising and marketing approvals, new indications or labeling for the investigational or accepted merchandise described on this media replace, or regarding potential future revenues from such merchandise. You shouldn’t place undue reliance on these statements. Such forward-looking statements are based mostly on our present beliefs and expectations regarding future occasions, and are topic to important recognized and unknown dangers and uncertainties. Should a number of of those dangers or uncertainties materialize, or ought to underlying assumptions show incorrect, precise outcomes could fluctuate materially from these set forth within the forward-looking statements. There may be no assure that the investigational or accepted merchandise described on this media replace might be submitted or accepted on the market or for any further indications or labeling in any market, or at any specific time. Nor can there be any assure that such merchandise might be commercially profitable sooner or later. In specific, our expectations regarding such merchandise might be affected by, amongst different issues, the uncertainties inherent in analysis and growth, together with medical trial outcomes and extra evaluation of present medical information; regulatory actions or delays or authorities regulation typically; international developments towards well being care value containment, together with authorities, payor and common public pricing and reimbursement pressures and necessities for elevated pricing transparency; our means to acquire or keep proprietary mental property safety; the actual prescribing preferences of physicians and sufferers; common political, financial and business circumstances, together with the results of and efforts to mitigate pandemic ailments equivalent to COVID-19; security, high quality, information integrity or manufacturing points; potential or precise information safety and information privateness breaches, or disruptions of our info know-how methods, and different dangers and elements referred to in Novartis AG’s present Form 20-F on file with the US Securities and Exchange Commission. Novartis is offering the knowledge on this media replace as of this date and doesn’t undertake any obligation to replace any forward-looking statements contained on this media replace because of new info, future occasions or in any other case.

About Novartis

Novartis is reimagining medication to enhance and prolong folks’s lives. As a number one international medicines firm, we use revolutionary science and digital applied sciences to create transformative therapies in areas of nice medical want. In our quest to search out new medicines, we persistently rank among the many world’s high firms investing in analysis and growth. Novartis merchandise attain almost 800 million folks globally and we’re discovering revolutionary methods to increase entry to our newest therapies. About 108,000 folks of greater than 140 nationalities work at Novartis all over the world. Find out extra at https://www.novartis.com.

Novartis is on Twitter. Sign as much as comply with @Novartis at https://twitter.com/novartisnews
For Novartis multimedia content material, please go to https://www.novartis.com/information/media-library
For questions concerning the website or required registration, please contact [email protected]

# # #

Novartis Media Relations
E-mail: [email protected]

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: [email protected]